Related references
Note: Only part of the references are listed.Multiple myeloma screening within a fracture liaison service (FLS)
G. Agarwal et al.
OSTEOPOROSIS INTERNATIONAL (2022)
Cutaneous manifestations of monoclonal gammopathy
Jean-Sebastien Claveau et al.
BLOOD CANCER JOURNAL (2022)
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study
Habib El-Khoury et al.
LANCET HAEMATOLOGY (2022)
Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
Charlotte Gran et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance
Rebecca Georgakopoulou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma - WGS Will Affect Future Treatment Decisions
Marietta Truger et al.
BLOOD (2021)
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
Li Pang et al.
BLOOD CANCER JOURNAL (2021)
Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort
Maxine J. E. Lamb et al.
BMJ OPEN (2021)
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events
Ola Landgren
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
Benedith Oben et al.
NATURE COMMUNICATIONS (2021)
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Saemundur Rognvaldsson et al.
BLOOD CANCER JOURNAL (2021)
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy
David F. Moreno et al.
CANCERS (2021)
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Pellegrino Musto et al.
HAEMATOLOGICA (2021)
A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
Ka-Won Kang et al.
SCIENTIFIC REPORTS (2021)
Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
Marta Lionetti et al.
CANCERS (2021)
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels
Jennifer L. J. Heaney et al.
HAEMATOLOGICA (2020)
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis*
Giulia Graziani et al.
LEUKEMIA & LYMPHOMA (2020)
The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions
Catherine Atkin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Monoclonal gammopathy of undetermined significance in medical hospital admissions - a new strategy for screening?
Ingemar Turesson
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls
Saemundur Rognvaldsson et al.
HAEMATOLOGICA (2020)
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
C. Ola Landgren et al.
LEUKEMIA (2020)
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma A Review
Francesco Maura et al.
JAMA ONCOLOGY (2020)
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Morie A. Gertz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
Angela Dispenzieri et al.
LEUKEMIA (2020)
Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)
Matthew Ho et al.
LEUKEMIA (2020)
Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016
Hilda O. Hounkpatin et al.
BMJ OPEN (2020)
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Oksana Zavidij et al.
NATURE CANCER (2020)
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients
Sanjay Kumar et al.
LEUKEMIA (2019)
Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia
Mark Bustoros et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Monoclonal Gammopathy May Be of Unpredictable Significance
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2019)
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Nelson Leung et al.
NATURE REVIEWS NEPHROLOGY (2019)
Early intervention effective in smouldering multiple myeloma
Elizabeth Gourd
LANCET ONCOLOGY (2019)
Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy
Jithendra Kini Bailur et al.
JCI INSIGHT (2019)
Pathophysiology and management of monoclonal gammopathy of renal significance
Ankur Jain et al.
BLOOD ADVANCES (2019)
Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
Normann Steiner et al.
ONCOTARGET (2018)
Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis
Benedikt W. Pelzer et al.
ANNALS OF HEMATOLOGY (2018)
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Jean-Paul Fermand et al.
BLOOD (2018)
IgE monoclonal gammopathy: A case report and literature review
C. Hejl et al.
CLINICAL BIOCHEMISTRY (2018)
Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort
Alexandra Smith et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2018)
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity
Mariana Ciocchini et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2017)
Monoclonal Gammopathye-Associated Peripheral Neuropathy: Diagnosis and Management
Hafsa M. Chaudhry et al.
MAYO CLINIC PROCEEDINGS (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study
John P. Campbell et al.
LANCET HAEMATOLOGY (2017)
Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
Shirley D'Sa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Hans Erik Johnsen et al.
HAEMATOLOGICA (2016)
Systemic amyloidosis
Ashutosh D. Wechalekar et al.
LANCET (2016)
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Hans Erik Johnsen et al.
HAEMATOLOGICA (2016)
Determining the Clinical Significance of Monoclonal Gammopathy of Undetermined Significance: A SEER-Medicare Population Analysis
Ronald S. Go et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma
Elin Edda Sigurdardottir et al.
JAMA ONCOLOGY (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
Overdiagnosis: How cancer screening can turn indolent pathology into illness
John Brodersen et al.
APMIS (2014)
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden
Ingemar Turesson et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network
Niels W. C. J. van de Donk et al.
HAEMATOLOGICA (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
O Landgren et al.
LEUKEMIA (2014)
Serial exome analysis of disease progression in premalignant gammopathies
S. Zhao et al.
LEUKEMIA (2014)
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Maria-Victoria Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Progression in smoldering Waldenstrom macroglobulinemia: long-term results
Robert A. Kyle et al.
BLOOD (2012)
Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests
Richard F. A. Logan et al.
GUT (2012)
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies
Mireille Broeders et al.
JOURNAL OF MEDICAL SCREENING (2012)
Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition
Terry M. Therneau et al.
MAYO CLINIC PROCEEDINGS (2012)
IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenstrom's Macroglobulinemia (SWM)
Robert A. Kyle et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Monoclonal gammopathy of undetermined significance: a consensus statement
James R. Berenson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
Celine M. Vachon et al.
BLOOD (2009)
Long-term follow-up of a population based cohort with monoclonal proteinaemia
Cees G. Schaar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
Jenny Bird et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients
John P. Bida et al.
MAYO CLINIC PROCEEDINGS (2009)
Prevalence of monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
SV Rajkumar et al.
BLOOD (2005)
Prognostic validation of the international classification of immunoglobulin M gammopathies: A survival advantage for patients with immunoglobulin m monoclonal gammopathy of undetermined significance?
PG Gobbi et al.
CLINICAL CANCER RESEARCH (2005)
The cervical cancer epidemic that screening has prevented in the UK
J Peto et al.
LANCET (2004)
Fracture risk in monoclonal gammopathy of undetermined significance
LJ Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Monoclonal gammopathy: Significance and possible causality in renal disease
P Paueksakon et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
